Benitec's Licensed Programs

Once proven in human clinical trials, ddRNAi technology has significant potential to treat or cure a broad range of human diseases - including cancers, neurological diseases, infectious diseases, autoimmune diseases, genetic diseases and other conditions associated with expression of a small number of key genes.

Several biotechnology companies have licensed Benitec's ddRNAi technology for use in their own human therapeutics programs. This table summarizes these licensed programs.



For details and status of each licensed program, use the links below.

See details of our in-house programs here.